Table 3

 Baseline adjusted robust regression for baseline serum soluble interleukin 2 receptor (sIL2R) predicting change in 28 joint disease activity score (DAS28) after six and 22 weeks

Explanatory variableDAS28 change from baseline
After 6 weeksAfter 22 weeks
Coefficient (95% CI)p ValueCoefficient (95% CI)p Value
Baseline sIL2R (per 100 U/ml)0.2054 (0.0035 to 0.4073)0.0470.0152 (−0.1872 to 0.2176)0.88
Baseline DAS28 score0.0585 (−0.5327 to 0.6498)0.84−0.3067 (−0.8730 to 0.2595)0.27
Infliximab dose (mg/kg)0.1313 (−0.3719 to 0.6346)0.590.0185 (−0.4515 to 0.4885)0.94
Constant−4.995 (−8.708 to −1.2823)−0.1731 (−3.220 to 2.873)